VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ACRS
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ACRSAclaris Therapeutics, Inc.
$3.90$545M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksACRSQuarterly Financials

Aclaris Therapeutics, Inc. (ACRS) Quarterly Income Statement

120+ quarters historyFree accessUpdated daily

Aclaris Therapeutics, Inc. (ACRS) quarterly income statement — complete revenue, gross profit & net income history

Income StatementBalance SheetCash FlowRatios

ACRS Income Statement

Quarterly statement

ACRS Income Statement

Aclaris Therapeutics, Inc. (ACRS) annual income statement — 13-year revenue, gross profit & net income history

AnnualQuarterly
MetricQ3'26Q2'26Q1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24Q1'24Q4'23Q3'23Q2'23Q1'23Q4'22Q3'22Q2'22Q1'22Q4'21
Sales/Revenue1.48M1.63M2M1.29M3.3M1.78M1.46M9.21M4.35M2.77M2.4M17.57M9.28M1.87M2.53M7.75M19.02M1.53M1.45M1.5M
Revenue Growth %-55.11%-8.33%37.18%-85.94%-24.09%-35.76%-39.32%-47.58%-53.18%47.99%-5.14%126.62%-51.19%22.32%73.98%416.52%1046.35%-16.23%-18.23%-5%
Cost of Goods Sold189K231K395K-803K538K1.85M506K9.3M2.41M1.91M1.84M6.43M8.19M1.59M1.87M1.51M8.22M1.07M1.16M1.15M
COGS % of Revenue12.76%14.18%19.79%-62.01%16.31%104.11%34.78%100.98%55.41%69.02%76.73%36.59%88.26%85.18%73.93%19.53%43.24%69.9%79.49%76.55%
Gross Profit1.29M1.4M1.6M2.1M2.76M-73K949K-90K1.94M857K558K11.14M1.09M277K659K6.24M10.79M460K298K352K
Gross Margin %87.24%85.82%80.21%162.01%83.69%-4.11%65.22%-0.98%44.59%30.98%23.27%63.41%11.74%14.82%26.07%80.47%56.76%30.1%20.51%23.45%
Gross Profit Growth %-53.21%2015.07%68.7%2431.11%42.47%-108.52%70.07%-100.81%77.8%209.39%-15.33%78.59%-89.9%-39.78%121.14%1672.44%1827.68%-18%-48.17%19.73%
Operating Expenses22.64M25.64M23.79M24.83M19.91M18.34M19.03M99.58M12.41M13.71M19.49M15.19M32.67M32.09M30.58M35.32M31.67M21.45M19.2M23.25M
OpEx % of Revenue1528.43%1573.73%1192.03%1917.53%603.52%1031.8%1308.11%1081.15%285.53%495.7%812.72%86.45%351.94%1717.07%1209.53%455.54%166.52%1404.06%1321.75%1548.63%
Selling, General & Admin6.04M6.05M6.74M5.58M4.87M5.39M6.14M4.95M5.65M4.65M6.84M8.21M6.8M7.3M8.79M7.15M5.81M6.08M6.1M6.94M
SG&A % of Revenue407.7%371.27%337.83%430.58%147.65%303.1%421.92%53.78%130.07%168.19%285.4%46.75%73.24%390.37%347.71%92.17%30.57%397.58%419.75%462.56%
Research & Development16.07M18.85M15.66M16.58M13.03M11.45M11.58M9.03M5.96M8.76M9.85M26.65M23.88M25.27M22.59M21.07M23.66M18.78M14.31M14.1M
R&D % of Revenue1084.81%1157.15%784.42%1280.62%394.91%644.29%796.15%97.99%137.05%316.67%410.55%151.66%257.23%1352.33%893.47%271.79%124.39%1228.99%984.58%939.51%
Other Operating Expenses532K738K1000K1000K1000K1000K1000K1000K800K300K1000K-1000K1000K-479K-800K1000K1000K-1000K-1000K1000K
Operating Income-21.34M-24.24M-22.19M-22.73M-17.15M-18.41M-18.08M-99.67M-10.47M-12.85M-18.93M-4.05M-31.58M-31.82M-29.92M-29.08M-20.87M-20.99M-18.91M-22.89M
Operating Margin %-1441.19%-1487.91%-1111.82%-1755.52%-519.82%-1035.9%-1242.89%-1082.13%-240.93%-464.71%-789.45%-23.03%-340.2%-1702.25%-1183.47%-375.07%-109.76%-1373.95%-1301.24%-1525.18%
Operating Income Growth %-24.46%-31.67%-22.72%77.19%-63.78%-43.21%4.47%-2362.94%66.84%59.6%36.72%86.08%-51.27%-51.54%-58.24%-27.02%-2.85%-16.59%33.73%-68.83%
EBITDA-21.34M-24.13M-22.09M-22.63M-17.04M-18.29M-17.96M-99.53M-10.29M-12.61M-18.69M-3.82M-31.36M-31.6M-29.72M-28.89M-20.68M-20.79M-18.7M-22.7M
EBITDA Margin %-1441.19%-1481.34%-1106.71%-1747.64%-516.49%-1029.49%-1234.09%-1080.58%-236.82%-455.97%-779.32%-21.74%-337.84%-1690.58%-1175.63%-372.62%-108.74%-1360.47%-1286.92%-1512.06%
EBITDA Growth %-25.27%-31.91%-23.02%77.26%-65.56%-45.05%3.92%-2506.23%67.18%60.08%37.12%86.78%-51.63%-52%-58.94%-27.29%-2.87%-17.06%33.79%-62.01%
D&A (Non-Cash Add-back)0107K102K102K110K114K128K143K179K242K243K228K219K218K198K190K193K206K208K197K
EBIT0-21.5M-19.82M-19.8M-14.61M-16.91M-17.78M-14.07M-9.67M-12.65M-16.13M-23.72M-29.58M-32.29M-30.72M-21.98M-18.67M-24.39M-20.11M-20.69M
Net Interest Income01.76M1.51M1.63M1.82M2.02M2.17M2.1M1.99M1.87M1.99M02.32M000-1.28M000
Interest Income1.85M1.76M1.51M1.63M1.82M2.02M2.17M2.1M1.99M1.87M1.99M02.32M000922K000
Interest Expense00000000000000002.2M000
Other Income/Expense2.83M2.73M2.37M2.94M2.54M2.98M3M3.12M2.88M1.87M1.99M2.19M2.32M2.25M1.76M1.44M922K462K118K89K
Pretax Income-18.51M-21.5M-19.82M-19.8M-14.61M-15.43M-15.09M-96.55M-7.59M-10.99M-16.94M-1.86M-29.26M-29.57M-28.16M-27.64M-19.95M-20.53M-18.79M-22.8M
Pretax Margin %-1249.83%-1320.14%-993.19%-1528.57%-442.98%-868.26%-1036.77%-1048.22%-174.55%-397.18%-706.46%-10.57%-315.24%-1582.08%-1113.92%-356.44%-104.91%-1343.72%-1293.12%-1519.25%
Income Tax00000000000-367K00000000
Effective Tax Rate %0%0%0%0%0%0%0%0%0%0%0%19.75%0%0%0%0%0%0%0%0%
Net Income-18.51M-21.5M-19.82M-19.8M-14.61M-15.43M-15.09M-96.55M-7.59M-10.99M-16.94M-1.49M-29.26M-29.57M-28.16M-27.64M-19.95M-20.53M-18.79M-22.8M
Net Margin %-1249.83%-1320.14%-993.19%-1528.57%-442.98%-868.26%-1036.77%-1048.22%-174.55%-397.18%-706.46%-8.49%-315.24%-1582.08%-1113.92%-356.44%-104.91%-1343.72%-1293.12%-1519.25%
Net Income Growth %-26.66%-39.38%-31.42%79.5%-92.64%-40.44%10.96%-6375.65%74.07%62.85%39.84%94.6%-46.66%-44.01%-49.87%-21.18%5.65%-13.06%34.66%-73.11%
Net Income (Continuing)-18.51M-21.5M-19.82M-19.8M-14.61M-15.43M-15.09M-96.55M-7.59M-10.99M-16.94M-1.49M-29.26M-29.57M-28.16M-27.64M-19.95M-20.53M-18.79M-22.8M
Discontinued Operations00000000000000000000
Minority Interest00000000000000000000
EPS (Diluted)-0.12-0.15-0.15-0.16-0.12-0.13-0.12-1.01-0.11-0.15-0.24-0.02-0.41-0.42-0.39-0.50-0.32-0.25-0.28-0.37
EPS Growth %0%-15.38%-25%84.16%-9.09%13.33%50%-4709.52%73.17%64.29%38.46%95.8%-28.13%-68%-39.29%-35.14%8.57%26.47%50.88%-23.33%
EPS (Basic)-0.12-0.15-0.15-0.16-0.12-0.13-0.12-1.01-0.11-0.15-0.24-0.02-0.41-0.42-0.39-0.50-0.32-0.25-0.28-0.37
Diluted Shares Outstanding149.45M142.74M128.81M122.66M122.62M122.58M122.39M95.31M71.38M71.29M71.07M70.87M70.81M70.63M66.87M66.69M66.68M65.99M61.43M61.23M
Basic Shares Outstanding149.45M142.74M128.81M122.66M122.62M122.58M122.39M95.31M71.38M71.29M71.07M70.87M70.81M70.63M66.87M66.69M66.68M65.99M61.43M61.23M
Dividend Payout Ratio--------------------